BNT Brookfield Wealth Solutions Ltd

Bentley Pharmaceuticals, Inc. (the �Company� or �Bentley�) (NYSE: BNT), today announced that its newly formed subsidiary, CPEX Pharmaceuticals, Inc., has filed an initial registration statement on Form 10 with the Securities and Exchange Commission (SEC) in furtherance of Bentley's plan to separate its drug delivery business from Bentley. Completion of the proposed spin-off is subject to numerous conditions, including final approval by Bentley�s Board of Directors and the effectiveness of the registration statement on Form 10, which is subject to review by the SEC. Bentley plans to spin off the drug delivery business in CPEX Pharmaceuticals as an independent, publicly traded company. Bentley plans to implement the spin-off through a taxable stock dividend of all CPEX Pharmaceuticals common stock to Bentley shareholders. CPEX Pharmaceuticals plans to seek a listing on the NASDAQ Capital Market under the ticker symbol �CPEX� and Bentley will continue to trade on the NYSE under its current ticker symbol �BNT.� Upon completion of the plan, Bentley will focus on the generics pharmaceutical business. Until CPEX Pharmaceuticals can fully establish its own operations, Bentley will provide transitional services, including managerial, operational and administrative support, for a period of up to 24 months. �Filing the Form 10 with the SEC is an important milestone for the planned spin-off of CPEX,� said James R. Murphy, Chairman and CEO of Bentley. �We are pleased with our progress and believe we are on track to complete the spin-off in a timely manner.� The Form 10 registration statement is posted on the SEC website at www.sec.gov under the name of CPEX Pharmaceuticals, Inc. CPEX Pharmaceuticals, Inc. CPEX Pharmaceuticals will focus on developing innovative drug delivery technologies based on the Company�s unique CPE-215 permeation enhancement technology. This technology has been validated through commercialization of Testim�, a testosterone gel marketed by Auxilium Pharmaceuticals, and is also currently being used to develop Nasulin�, an intranasal insulin product. Following the consummation of the spin-off, CPEX Pharmaceuticals will be based in Exeter, NH and will employ approximately 20 individuals. Forward-Looking Statements This press release contains certain forward-looking statements, which are based on management�s good faith expectations and beliefs concerning future developments of Bentley and CPEX Pharmaceuticals. Forward-looking statements can be identified by the use of words such as �in the future,� �will,� �may,� �believe,� �expect,� �plans,� �strategy,� �intends,� and �estimate.� Statements that refer to Bentley�s or CPEX Pharmaceuticals� plans for executing the spin-off, the taxable nature and timing of the spin-off, and future prospects of the companies as independent companies, and the like, are forward-looking statements that reflect the Company�s current analysis of existing trends, information and current plans. Actual results may differ from current expectations based on a number of factors affecting the Company�s businesses, including changing competitive, regulatory and market conditions; inherent uncertainty associated with financial projections, which cannot be predicted with certainty; unpredictability associated with the timing and the results of both the research and development and regulatory processes; domestic and foreign health care and cost containment reforms; technological advances and patents obtained by competitors; approval, introduction and consumer acceptance of new products and continuing acceptance of currently marketed products; timely and successful implementation of strategic alternatives; uncertainty associated with the identification of and successful execution of external corporate development transactions and strategic alliance partners; each company�s ability to obtain and maintain a sufficient supply of its products to meet market demand in a timely manner; matters affecting the economy in general, such as changes in interest and currency exchange rates; the uncertainties associated with effecting a spin-off of a separate public company; the discretion of Bentley�s Board of Directors to delay or cancel the spin-off prior to execution; and other uncertainties detailed in Bentley�s most recent Annual Report on Form 10-K and its other subsequent periodic reports filed with the Securities and Exchange Commission, as well as the risks set forth in the "Risk Factors" section of the CPEX Form 10 registration statement. The Company disclaims any intent or obligation to update these forward-looking statements.